AC Immune Ltd (ACIU) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AC Immune Ltd (ACIU) has a cash flow conversion efficiency ratio of -0.366x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.45 Million) by net assets ($44.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see AC Immune Ltd (ACIU) total market value for the company's overall valuation and market capitalisation.
AC Immune Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how AC Immune Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
AC Immune Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AC Immune Ltd ranked by their cash flow conversion efficiency. Explore AC Immune Ltd cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Medallion Financial Corp
NASDAQ:MFIN
|
0.035x |
|
BenQ Materials Corp
TW:8215
|
-0.005x |
|
Ainsworth Game Technology Ltd
AU:AGI
|
-0.022x |
|
LCNB Corporation
NASDAQ:LCNB
|
0.031x |
|
Peach Property Group AG
SW:PEAN
|
-0.008x |
|
Portillo's Inc
NASDAQ:PTLO
|
0.034x |
|
Wireless Power Amplifier Module Inc
KQ:332570
|
-0.129x |
|
Motech Industries Co Ltd
TWO:6244
|
0.132x |
Annual Cash Flow Conversion Efficiency for AC Immune Ltd (2013–2025)
The table below shows the annual cash flow conversion efficiency of AC Immune Ltd from 2013 to 2025. View current stock price of AC Immune Ltd for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $44.93 Million | $-66.15 Million | -1.472x | -351.01% |
| 2024-12-31 | $112.27 Million | $65.84 Million | 0.586x | +255.96% |
| 2023-12-31 | $160.64 Million | $-60.41 Million | -0.376x | +13.62% |
| 2022-12-31 | $168.99 Million | $-73.57 Million | -0.435x | -53.74% |
| 2021-12-31 | $231.98 Million | $-65.69 Million | -0.283x | -2.52% |
| 2020-12-31 | $215.48 Million | $-59.52 Million | -0.276x | -236.27% |
| 2019-12-31 | $272.44 Million | $55.22 Million | 0.203x | +181.68% |
| 2018-12-31 | $177.62 Million | $-44.08 Million | -0.248x | -31.23% |
| 2017-12-31 | $116.84 Million | $-22.09 Million | -0.189x | -376.86% |
| 2016-12-31 | $142.38 Million | $-5.65 Million | -0.040x | -106.39% |
| 2015-12-31 | $71.04 Million | $44.08 Million | 0.621x | +182.63% |
| 2014-12-31 | $23.47 Million | $-17.62 Million | -0.751x | +81.57% |
| 2013-12-31 | $4.86 Million | $-19.80 Million | -4.075x | -- |
About AC Immune Ltd
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins … Read more